Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 3, Issue 4, Pages 199-207Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620712445329
Keywords
CD20; therapeutic monoclonal antibodies; chronic lymphocytic leukemia; ofatumumab
Categories
Ask authors/readers for more resources
There are now many therapeutic CD20 monoclonal antibodies undergoing clinical trials for B-cell malignancy and autoimmune conditions; which is optimal for cancer therapy is not clear. The novel human IgG1 CD20 monoclonal antibody ofatumumab has shown significant activity in difficult to treat patients with chronic lymphocytic leukemia, namely those resistant or refractory to fludarabine and alemtuzumab and has now been licensed for this uncommon indication. This brief review summarizes the clinical data obtained with ofatumumab in CLL in terms of both efficacy and toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available